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Introduction 
Blood loss and bleeding tendency with the consequence of homologous blood trans-
fusion still present a major problem in cardiac surgery. Many efforts have been made 
to influence the bleeding tendency in open-heart surgery by pharmacological means. 
Aprotinin is a naturally occurring enzyme inhibitor derived from bovine lungs. It 
acts on trypsin, plasmin, tissue-kallikrein and, to lesser degree, on plasma-kallikrein 
[1 ,2] . Moreover, it is reported to have direct platelet-preserving properties in very 
high dosages [3]. Aprotinin has been used in Europe for a long time in varying 
indications, but only since the results published by Royston et al. [4] who applied 
very high dosages of aprotinin, has this drug been regarded with increased interest. 
Recently, these results were corroborated by several studies [5—9]. 
Based upon previous investigations [7], we postulated that the clinical effect of 
aprotinin is mainly due to the inhibition of the contact phase of coagulation. During 
CPB this system is activated by contact of blood with artificial surfaces of the ex-
tracorporeal circuit [10]. However, the postoperative bleeding tendency after cardiac 
surgery seems to be primarily due to impaired platelet function [11]. But the mech-
anism underlying the benefit from aprotinin has not yet been elucidated completely. 
The aim of our present prospective, double-blind, placebo controlled study was 
to obtain further information about the mode of action of aprotinin. 
Methods 
Forty patients scheduled for elective primary myocardial revascularization gave in-
formed consent to participate in this study, which had been approved by the local 
ethics committee. The study group comprised only male patients with preoperative 
normal left ventricular function (EF > 40%, LVEDP < 20 mmHg), with a preop-
erative hemoglobin concentration > 13.5 g/dl, and who were not receiving preop-
erative anticoagulant treatment or antiplatelet medication. 
Patients were randomly assigned to one of two groups: the aprotinin group (group 
A) and the control (group C). The following dosage regime of aprotinin was applied: 
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after induction of anesthesia and prior to surgery, patients received a loading dose 
of 2 x 106 KIU aprotinin over a 15-min period, followed by a continuous infusion 
of 5 x 105 KIU per hour administered by an infusion pump during the whole time 
of surgery. An additional bolus of 2 x 106 KIU was added to the pump prime of the 
heart-lung machine. Patients of group C received an equal volume of saline. 
The indication for intra- and postoperative transfusion of homologous blood or 
blood products was defined in the study protocol as a hematocrit of less than 30 °/o. 
Anesthetic, operative, and bypass management were standardized. Patients were 
heparinized with 125 units/kg mucosa heparin. Further heparin (125 units/kg) was 
administered if the activated clotting time (ACT) decreased below 400 s. The extra-
corporeal circuit consisted of a bubble oxygenator, which was primed with 1400 ml 
crystalloid solution. After completion of CPB, residual heparin was neutralized with 
protamine chloride in a ratio of 1.5 mg per 125 units of the initial heparin dosage. 
Blood transfusions needed until discharge from the hospital were recorded. Intra-
operative blood loss was assessed by weighing the gauzes and sponges and measuring 
the content of the suction reservoir. Postoperative blood loss was measured as cu-
mulative chest tube output 6, 12, and 24 h postoperatively, as well as at the removal 
of the chest tubes. 
Blood samples were taken at the following times: 1) after induction of anesthesia 
and prior to aprotinin infusion; 2) prior to heparin administration; 3) 5 min and 4) 
30 min after start of CPB; 5) at the end of CPB; 6) after chest closure. After dis-
carding the first 10 ml. blood was drawn into EDTA tubes or into ACC solution 
( 4 : 1 ) . 
Tissue plasminogen activator (tPA) concentration, the split products of cross-
linked fibrin (D-dimers), total degradation products of fibrinogen and fibrin (FSP), 
and the complex of thrombin with antithrombin III (TAT) [12] were determined by 
sandwich ELISA's using polyclonal as well as monoclonal antibodies. Results are 
given in ng/ml. Aprotinin plasma concentrations were quantified by means of a 
competitive ELISA, according to Müller-Esterl et al. [13]. Spontaneous fibrinolytic 
activation in the native samples, as well as in their euglobulin fraction, was esti-
mated on plasminogen containing human fibrin plates [14]. 
To determine the ACT, the Hemochron 800 (International Technidine Corp., New 
Jersey, USA) was used. ACT measurements were performed every 30 min and at all 
intraoperative measurement times. 
Summary data of all variables are expressed as means ± standard deviation (SD). 
Analysis of variance (ANOVA) was used if appropriate. Chi-square test was applied 
for categorical data. A p value less than 0.05 was considered statistically significant. 
Results 
Patients' demographic data were comparable in terms of age, weight, operation, and 
CPB time. Thirteen patients in group C and 11 patients in group A had an additional 
internal mammary artery implantation. 
The assessed intraoperative blood loss was 636 ± 322 ml in group C and 
363 ± 159 ml in group A (p < 0.05). The mean cumulated loss 6, 12 and 24 h 
postoperatively was 721 ±471 ml, 894 ± 491 ml, and 1169 ± 605 ml in group C, 
and 303 ± 209 ml, 399 ± 251 ml, and 584 ± 295 ml in group A. The total post-
operative blood loss until removal of the chest tubes was 1431 ± 760 ml in group 
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C, and 738 ±411 ml in group A (p < 0.05) (Fig. 1). The mean amount of intra-
and postoperatively transfused homologous blood was 838 ± 963 ml/patient in 
group C and 163 ± 308 ml in group A, respectively (p < 0.05). 2.3 ± 2.2 units of 
homologous blood or blood products were given in group C and 0.63 ± 0.96 units/ 
patient in group A (p < 0.05). Twenty-five % of the patients in group C and 63% 
in group A were discharged from the hospital without receiving any banked blood 
or homologous blood products. The intraoperative blood loss correlated signifi-
cantly with CPB time in group C, whereas it did not in group A. 
The ACT, which was in a comparable range preoperatively in the two groups, was 
significantly increased 5 min prior to administration of heparin in group A 
(141 ± 13 vs 122 ± 25 s) and remained significantly higher until antagonizing the 
effect of heparin after CPB. The aPTT was also significantly increased before hep-
arin in group A (34 ± 2.8 vs 74 ± 7.3 s) (p < 0.05) and remained significantly 
prolonged until 2 h post surgery (66 ± 23 vs 45 ± 25 s). 
The concentration of the TAT complex 30 min after the start of CPB and at the 
end of CPB showed significant differences (p < 0.05) with 48 + 21 and 82 ± 42 
ng/ml (group C) compared to 24 ± 11 and 42 ± 14 ng/ml in group A. 
The concentration of the split products of the cross-linked fibrin (D-dimers) in-
creased in both groups during surgery. However, the increase was less in the apro-
tinin group and was 532 ± 1425 and 497 + 1398 ng/ml, 30 m in after onset of CPB 
and at the end of CPB, respectively, significantly less than the values of group C 
(2155 ± 2300 and 3131 ± 2755 ng/ml). The FSP concentrations showed a similar 
course (Fig. 2). At the end of CPB the concentration was 10 824 ± 7261 ng/ml in 
group C and 2510 ± 3932 ng/ml in the aprotinin group (p < 0.05). 
The fibrin plates revealed increased fibrinolytic activity during the entire course 
of CPB in the control group. In the native samples fibrinolytic activity was evident 
[ml] 
2000 
intraoperative 6 hours 12 hours postop 
postop postop total 
Fig. 1. Intra- and postoperative blood loss. The postoperative data are cumulative values. 
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Fig. 2. Total degradation products of fibrinogen and fibrin. Values shown in the graph are mean ± 
SD. There was a significant increase during the whole period of CPB in the control group compared 
to the aprotinin group. 
in 12 patients/5 min and in 13 patients/30 min after onset of CPB in the control 
group, whereas this could not be demonstrated 5 min after start of CPB, and in 8 
patients/30 min after start of CPB in the aprotinin group (p < 0.05). The tPA con-
centration was not significantly different during the course of surgery. 
The aprotinin plasma concentration (Fig. 3) demonstrated an increase from 
152 ± 61 KlU/ml prior to heparin to 335 ± 106 KlU/ml 5 min after onset of CPB. 
Thereafter, a continuous decrease was found until the end of CPB (191 ± 62 KIU/ 
ml). 
The postoperative course of all patients was uneventful. There were no clinically 
relevant side effects that could be attributed to aprotinin treatment. 
Discussion 
The present study demonstrates the influence of high-dose aprotinin treatment on 
intra- and postoperative blood loss. Comparing homogeneous patient groups, a sig-
nificant reduction of intra- and postoperative blood loss was found in the aprotinin-
treated group. This reduction led to a concomitant saving of homologous blood. The 
postoperative blood loss was reduced by 48%, whereas the banked blood require-
ment was diminished by nearly 80%. 
The differences between the two groups with regard to bleeding and banked blood 
requirement agree with the results of other authors applying the same or a similar 
aprotinin dosage regime. The blood-saving effect in these studies varied between 
43% [7] and 88% [4] (Table 1). All studies using aprotinin during coronary artery 
bypass grafting showed nearly identical reductions in blood loss. 
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[KlU/ml] 
450-
O 400-
prior to 5 min after 30 min after CPB end end of 2 hours 
heparin CPB start CPB start operation postop 
Fig. 3. Aprotinin plasma level. The peak value 5 min after the onset of CPB represents the bolus of 
2 x 106 KIU aprotinin given to the pump prime. Despite the continuous infusion of 5 x 105 KIU 
aprotinin/h the concentration decreased towards the end of CPB and towards the end of operation. 
Table 1. Studies on aprotinin in open-heart surgery. 
Autor Year Type of No. of Blood Blood 
operation patients loss saving 
Royston et al. [4] 1987 Redos 22 - 8 0 % 88% 
v. Oeveren et al. [15] 1987 CABG 22 - 4 7 % - 50% 
Bidstrup et al. [6] 1989 CABG 80 - 4 6 % - 8 3 % 
Dietrich et al. [7] 1989 Miscellaneous 152 - 2 9 % - 4 3 % 
Fraedrich et al. [8] 1989 CABG 80 - 4 6 % - 4 3 % 
Henze et al. [16] 1989 Miscellaneous 380 - 3 5 % - 4 0 % 
Dietrich et al. [17] 1989 CABG 40 - 4 8 % - 8 0 % 
Dietrich et al. [18] 1990 Miscellaneous 1784 - 34% - 5 3 % 
Nevertheless, the mode of action of aprotinin is not yet completely clear. Capillary 
bleeding and oozing in cardiac surgery are supposed to be due to impaired platelet 
function [11, 19]. The most important consequence of CPB is the loss of platelet 
aggregability [10]. The influence of aprotinin on platelet adhesive receptors could 
be demonstrated in one study [9]. Consequently, a direct platelet-preserving prop-
erty of aprotinin has been postulated [9, 15]. 
The surface-mediated activation of the contact system of coagulation involves the 
interaction of Factor XII (Hageman factor) and kallikrein (besides high molecular 
weight kininogen and Factor XI) [20]. Aprotinin may inhibit kallikrein. Without 
the amplifying effect of kallikrein on the conversion of Factor XII to Xlla the con-
tact phase activation is inhibited or takes place only slowly. Major consequences of 
the surface-mediated activation are the stimulation of both the intrinsic pathway of 
coagulation [21] with the effect of thrombin formation and the propagation of the 
fibrinolytic pathway leading to plasminogen activation. Thrombin is a powerful 
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platelet activator. Therefore, it is conceivable that the effect of aprotinin on platelets 
is secondary to the inhibition of the contact system of coagulation (Fig. 4) 
Aprotinin is a strong plasmin inhibitor [22]. While we observed differences in the 
results of the fibrin plates between the groups, we could no detect any significant 
difference in the course of tPA concentration. The current findings indicate, that 
endothelial activation of fibrinolysis is not inhibited by aprotinin, whereas the ac-
tivation via plasma kallikrein is attenuated. The course of the ACT, which is an 
indicator of contact activation [23], as well as the aPTT elevation with aprotinin 
treatment refer to the inhibition of the contact phase of coagulation. These hemo-
stasiological results strongly suggest, that the inhibition of the contact phase of co-
agulation is the primary effect of aprotinin and is thus responsible for its blood-
saving effect. This finding is in contrast to the interpretation given by van Oeveren 
et al. [9, 15], who focused on the direct platelet protective effect of aprotinin on the 
specific platelet receptors. 
The rationale for choosing the given aprotinin dose regime was to get a constant 
aprotinin plasma level of more than 200 KIU/ml, which is supposed to be the thresh-
old of plasma kallikrein inhibition [24]. The course of plasma aprotinin level re-
vealed that aprotinin dosage was not able to maintain a stable concentration 
throughout CPB. However, the concentration exceeded 200 KIU/ml after onset of 
CPB. The course of the fibrin-fibrinogen split products and the results of the fibrin 
plates demonstrated that aprotinin was not able to suppress the ongoing hemostatic 
activation totally. All parameters showed an increase towards the end of CPB. Fur-
ther investigation is needed to ascertain whether this tendency can be prevented 
with an even higher dose regime of aprotinin during CPB. 
Complement 
System 
Angiotensin 
System 
Kinin 
generation 
Aprotinin 
Aprotinin 
\ ii Coagulation XII 
Kallikrein 
XI t HMWK f I Y Xlla J * 
Prekallikrein i 
surface 
activation 
^ Plasmin 
XIa 
Xa 
Thrombin 
Plasminogen 
activation 
inhibition 
Fibrinolysis Platelets 
Fig. 4. Aprotinin action on the hemostatic system. 
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The results of this study suggest that the most likely mechanism of action of 
aprotinin is the inhibition of the contact phase of coagulation. This is due to the 
ability of aprotinin to inhibit kallikrein. It acts supplementary to heparin on coa-
gulation. The combination of both drugs provides an enhanced anticoagulatory ef-
fect. However, because aprotinin only acts on the contact phase of coagulation, it is 
not recommended to reduce the heparin dosage under aprotinin. The better pre-
served platelet function and the inhibition of fibrinolysis is secondary to the better 
preserved coagulation system. 
In conclusion, high-dose aprotinin treatment has a highly beneficial effect on the 
hemostatic mechanism during and after CPB, leading to a substantial reduction of 
intra- and postoperative bleeding tendency. The most likely mechanism of aprotinin 
action is the inhibition of kallikrein and not a direct platelet-preserving property. 
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